Antibodies News and Research

RSS

The Automation Partnership's ambr technology to be previewed at the Bioprocess International Conference

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is exclusively previewing its Advanced Microscale BioReactor (ambr™) technology on Booth 914 at the Bioprocess International Conference in Raleigh, USA.

13 Oct 2009

Educational video on seasonal and H1N1 vaccines development

Will a four-minute educational video about a team of Air Force researchers investigating the H1N1 influenza virus go "viral" with middle- and high-school students?

12 Oct 2009

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Selexis SA and Irvine Scientific Inc. announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.

12 Oct 2009

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

Manchester scientists test radioimmunotherapy in early phase clinical trials

MANCHESTER SCIENTISTS are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

9 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

Phadia launches new, advanced assays for accurate diagnosis of celiac disease

Phadia Inc., worldwide leaders in the development, manufacturing and marketing of complete blood test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases, today announced the launch of a two new, highly -reliable assays to support the accurate diagnosis of celiac disease.

8 Oct 2009

Coeliac disease patients at risk of osteoporosis

People with coeliac disease may develop osteoporosis because their immune system attacks their bone tissue, a new study has shown.

8 Oct 2009

The Prescription Center Pharmacy launches 'Be Prepared, Not Scared' campaign

The Prescription Center Pharmacy, headquartered in Beverly Hills, California announced its “Be Prepared, Not Scared” campaign today. The purpose of the campaign is to help both businesses and consumers stay healthy, without dramatically changing their daily routines. Dr. Afshin Nassir, the pharmacy’s Founder and CEO, states that “We want to help businesses and consumers create a realistic plan to deal with the H1N1 (Swine Flu) Virus, which is now, according to the Center for Disease Control (CDC), at a Pandemic stage.”

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Research finds 50 million people vaccinated against zoonotic brain infection

Research at the University of Liverpool has supported the vaccination of more than 50 million people against a zoonotic brain infection that affects thousands of children across Asia every year.

7 Oct 2009

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow.

7 Oct 2009

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

The winner of the 2009 EUROPEAN BIOTECHNICA AWARD is NovImmune SA from Switzerland. This biopharmaceutical company duly receives the lion’s share of the €100,000 prize money, which is awarded each year by Deutsche Messe AG and its partners. The aim of the award is to celebrate the achievements of innovative European companies in the field of biotechnology and the life sciences.

6 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Vaccine to treat cocaine dependence reduces use of the drug, according to study

A vaccine to treat cocaine dependence appears to reduce use of the drug in a subgroup of individuals who attain high anticocaine antibody levels in response, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals. However, only 38 percent of vaccinated individuals produced high enough antibody levels and those who did maintained them for only two months.

6 Oct 2009

Antibodies News and Research

The Automation Partnership's ambr technology to be previewed at the Bioprocess International Conference

Educational video on seasonal and H1N1 vaccines development

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Manchester scientists test radioimmunotherapy in early phase clinical trials

New cancer drugs boost drug spending

Phadia launches new, advanced assays for accurate diagnosis of celiac disease

Coeliac disease patients at risk of osteoporosis

The Prescription Center Pharmacy launches 'Be Prepared, Not Scared' campaign

NCI awards $11.5 million grant to UAB for cervical cancer research

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Research finds 50 million people vaccinated against zoonotic brain infection

Scientists create new technology to improve detection of leukemia cells in bone marrow

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

Vivaldi receives US patent for live attenuated influenza vaccines

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

Vaccine to treat cocaine dependence reduces use of the drug, according to study

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo